Heidari Majd Mostafa, Barar Jaleh, Asgari Davoud, Valizadeh Hadi, Rashidi Mohammad Reza, Kafil Vala, Shahbazi Javid, Omidi Yadollah
Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. ; Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran. ; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Adv Pharm Bull. 2013;3(1):189-95. doi: 10.5681/apb.2013.031. Epub 2013 Feb 7.
To achieve simultaneous imaging and therapy potentials, targeted fluoromagnetic nanoparticles were synthesized and examined in human breast cancer MCF-7 cells.
Fe3O4 nanoparticles (NPs) were synthesized through thermal decomposition of Fe(acac)3. Then, magnetic nanoparticles (MNPs) modified by dopamine-poly ethylene glycol (PEG)-NH2; finally, half equivalent fluorescein isothiocyanate (FITC) and half equivalent folic acid were conjugated to one equivalent of it. The presence of Fe3O4-DPA-PEG-FA/FITC in the folate receptor (FR) positive MCF-7 cells was determined via fluorescent microscopy to monitor the cellular interaction of MNPs.
FT-IR spectra of final compound confirmed existence of fluorescein on folic acid grafted MNPs. The Fe3O4-DPA-PEG-FA/FITC NPs, which displayed a size rang about 30-35 nm using scanning electron microscopy (SEM) and transmission electron microscopy (TEM), were able to actively recognize the FR-positive MCF-7 cells, but not the FR-negative A549 cells.
The uniform nano-sized Fe3O4-DPA-PEG-FA/FITC NPs displayed great potential as theranostics and can be used for targeted imaging of various tumors that overexpress FR.
为实现同步成像和治疗潜力，合成了靶向荧光磁性纳米颗粒并在人乳腺癌MCF-7细胞中进行检测。
通过热分解Fe(acac)3合成Fe3O4纳米颗粒（NPs）。然后，用多巴胺-聚乙二醇（PEG）-NH2修饰磁性纳米颗粒（MNPs）；最后，将半当量的异硫氰酸荧光素（FITC）和半当量的叶酸与一当量的该物质共轭。通过荧光显微镜确定叶酸受体（FR）阳性的MCF-7细胞中Fe3O4-DPA-PEG-FA/FITC的存在，以监测MNPs与细胞的相互作用。
最终化合物的傅里叶变换红外光谱（FT-IR）证实了叶酸接枝的MNPs上存在荧光素。使用扫描电子显微镜（SEM）和透射电子显微镜（TEM）显示尺寸范围约为30-35nm的Fe3O4-DPA-PEG-FA/FITC NPs能够主动识别FR阳性的MCF-7细胞，但不能识别FR阴性的A549细胞。
均匀的纳米级Fe3O4-DPA-PEG-FA/FITC NPs作为诊疗试剂显示出巨大潜力，可用于对过表达FR的各种肿瘤进行靶向成像。
